Gate News Report, April 29 — American pharmaceutical company Eli Lilly announced on April 28 that it has signed a deal worth up to $2.25 billion with AI biotech startup Profluent to develop DNA editing drugs. Lilly will obtain exclusive rights to any drugs resulting from the collaboration.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments